|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date04 Jun 2021 |
Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date12 Nov 1998 |
Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date12 Nov 1998 |
100 Clinical Results associated with Emergent Biodefense Operations Lansing LLC
0 Patents (Medical) associated with Emergent Biodefense Operations Lansing LLC
100 Deals associated with Emergent Biodefense Operations Lansing LLC
100 Translational Medicine associated with Emergent Biodefense Operations Lansing LLC